Abstract Respiratory Syncytial Virus (RSV) infection is the leading cause of lower respiratory
tract infection in both young children and older adults. Currently, there is no licensed vaccine …

Respiratory syncytial viruses (RSV) are one of the most important respiratory pathogens of
humans and cattle, and there is currently no safe and effective vaccine prophylaxis. In this …

Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections
causing pneumonia and bronchiolitis in infants. RSV also causes serious illness in elderly …

Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infections in
children, yet no vaccine is available. The sole licensed preventive treatment against RSV is …

Respiratory syncytial virus is the most important cause of lower respiratory tract infection in
infants and young children. RSV clinical disease varies from rhinitis and otitis media to …

The mature F protein of all known isolates of human respiratory syncytial virus (HRSV)
contains fifteen absolutely conserved cysteine (C) residues that are highly conserved among …

Respiratory syncytial virus (RSV) is a significant cause of severe respiratory illness
worldwide, particularly in infants, young children, and the elderly. Although no licensed …

The attachment glycoprotein (G) of respiratory syncytial virus (RSV) is synthesized as two
mature forms: a membrane-anchored form and a smaller secreted form. Mutant cDNAs were …

A recombinant human antibody fragment, designated RSV Fab 19, efficiently neutralizes
respiratory syncytial virus (RSV). Here we report the results of our sequence analysis of …

Premature infants and those with chronic lung disease or congenital heart disease are at
high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a …